Infliximab
10
4
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
70%
7 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease
Combined Immunosuppression for Pediatric Crohn's Disease
Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease
Investigation of the Correlation Between Polyamine Levels and Their Key Enzymatic Activities in Association With Inflammatory Bowel Disease Progression
TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
Top Down Versus Step up in Pediatric Ulcerative Colitis
HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease
Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients
A Clinical Trial of Infliximab for Childhood Uveitis
Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis